Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP.

J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550.

PMID:
19561230
2.

Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.

Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M, Gevensleben H, Büttner R, Schildhaus HU, Wardelmann E.

Hum Pathol. 2017 Apr;62:206-214. doi: 10.1016/j.humpath.2017.01.005. Epub 2017 Feb 1. Review.

PMID:
28159677
3.

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Lasota J, Miettinen M.

Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Review.

PMID:
18312355
4.

Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.

Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR.

J Pediatr Hematol Oncol. 2005 Apr;27(4):179-87. Review.

PMID:
15838387
5.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC.

J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. Review.

PMID:
15928335
6.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
7.

An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).

Nannini M, Biasco G, Astolfi A, Pantaleo MA.

J Med Genet. 2013 Oct;50(10):653-61. doi: 10.1136/jmedgenet-2013-101695. Epub 2013 Jul 5. Review.

PMID:
23833252
8.

Genetics of Gastrointestinal Stromal Tumors: A Heterogeneous Family of Tumors?

Patil DT, Rubin BP.

Surg Pathol Clin. 2015 Sep;8(3):515-24. doi: 10.1016/j.path.2015.05.006. Epub 2015 Jul 7. Review.

PMID:
26297068
9.

Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.

Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, Wardelmann E.

Expert Rev Anticancer Ther. 2015 Jun;15(6):623-8. doi: 10.1586/14737140.2015.1032941. Epub 2015 Apr 1. Review.

PMID:
25831232
10.

Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.

Doyle LA, Hornick JL.

Histopathology. 2014 Jan;64(1):53-67. doi: 10.1111/his.12302. Epub 2013 Nov 28. Review.

PMID:
24117705
11.

Myxoid epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literature.

Tajima S, Ohata A, Koda K, Maruyama Y.

Int J Clin Exp Pathol. 2015 May 1;8(5):5821-9. eCollection 2015. Review.

12.

Gastrointestinal stromal tumors: what do we know now?

Corless CL.

Mod Pathol. 2014 Jan;27 Suppl 1:S1-16. doi: 10.1038/modpathol.2013.173. Review.

13.

Clinical implications of KIT and PDGFRA genotyping in GIST.

Martín-Broto J, Rubio L, Alemany R, López-Guerrero JA.

Clin Transl Oncol. 2010 Oct;12(10):670-6. doi: 10.1007/s12094-010-0576-7. Review.

PMID:
20947481
14.

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.

Wozniak A, Floris G, Debiec-Rychter M, Sciot R, Schöffski P.

Cancer Invest. 2010 Oct;28(8):839-48. doi: 10.3109/07357907.2010.494322. Review.

PMID:
20690803
15.

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Boikos SA, Stratakis CA.

Endocrine. 2014 Nov;47(2):401-8. doi: 10.1007/s12020-014-0346-3. Epub 2014 Jul 16. Review.

16.

Cancer biology of small gastrointestinal stromal tumors (<2 cm): What is the risk of malignancy?

Søreide K.

Eur J Surg Oncol. 2017 Jul;43(7):1344-1349. doi: 10.1016/j.ejso.2017.01.240. Epub 2017 Feb 9. Review.

PMID:
28222971
17.

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.

Maleddu A, Pantaleo MA, Nannini M, Biasco G.

J Transl Med. 2011 May 23;9:75. doi: 10.1186/1479-5876-9-75. Review.

18.
19.

Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.

Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU.

Virchows Arch. 2007 Oct;451(4):743-9. Epub 2007 Aug 14. Review.

PMID:
17701051
20.

Clinical implications of mutational analysis in gastrointestinal stromal tumours.

Hoeben A, Schöffski P, Debiec-Rychter M.

Br J Cancer. 2008 Feb 26;98(4):684-8. doi: 10.1038/sj.bjc.6604217. Epub 2008 Feb 5. Review.

Supplemental Content

Support Center